TAK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 10:47):

Stats
Today's Volume	329 535
Average Volume	1.83M
Market Cap	41.09B
EPS	$0 ( 2024-02-01 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0.270 ( 2022-09-29 )
Next Dividend	$0 ( N/A )
P/E	36.38
ATR14	$0.00600 (0.05%)

Volume Correlation

Long: 0.23 (neutral)

Short: 0.04 (neutral)

Signal:(38.717) Neutral

Takeda Pharmaceutical Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Takeda Pharmaceutical Correlation - Currency/Commodity

-0.55
( weak negative )

-0.11
( neutral )

0.00
( neutral )

-0.67
( moderate negative )

0.00
( neutral )

-0.32
( neutral )

Takeda Pharmaceutical Financials

Annual	2023
Revenue:	$4 027.48B
Gross Profit:	$2 783.41B (69.11 %)
EPS:	$204.29

Q3	2024
Revenue:	$1 111.19B
Gross Profit:	$731.71B (65.85 %)
EPS:	$67.38

Q2	2024
Revenue:	$1 043.09B
Gross Profit:	$699.51B (67.06 %)
EPS:	$-30.68

Q1	2024
Revenue:	$1 058.62B
Gross Profit:	$737.50B (69.67 %)
EPS:	$57.51

Financial Reports:

No articles found.

Takeda Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.270 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Takeda Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.76 - low (58.20%) | Divividend Growth Potential Score: 3.01 - Decrease likely (39.80%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.470	2008-09-25
Last Dividend	$0.270	2022-09-29
Next Dividend	$0	N/A
Payout Date	2022-12-12
Next Payout Date	N/A
# dividends	27	--
Total Paid Out	$11.88	--
Avg. Dividend % Per Year	1.27%	--
Score	2.45	--
Div. Sustainability Score	4.76
Div.Growth Potential Score	3.01
Div. Directional Score	3.89	--

Next Divdend (Est)
(2024-08-15)

$0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

2.45

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2008	$0.470	3.54%
2009	$1.000	6.24%
2010	$0.533	4.02%
2011	$1.135	7.11%
2012	$1.110	7.35%
2013	$0.894	5.57%
2014	$0.822	4.87%
2015	$0.730	4.62%
2016	$0.829	4.27%
2017	$0.798	4.71%
2018	$0.802	3.34%
2019	$0.828	4.92%
2020	$0.850	4.27%
2021	$0.804	4.47%
2022	$0.270	1.96%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0427	1.500	9.15	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0125	1.200	9.58	10.00	[0 - 0.3]
returnOnEquityTTM	0.0263	1.500	-0.819	-1.228	[0.1 - 1]
payoutRatioTTM	1.619	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.064	0.800	9.68	7.74	[1 - 3]
quickRatioTTM	0.465	0.800	-1.972	-1.578	[0.8 - 2.5]
cashRatioTTM	0.126	1.500	-0.409	-0.614	[0.2 - 2]
debtRatioTTM	0.328	-1.500	4.53	-6.80	[0 - 0.6]
interestCoverageTTM	1.450	1.000	-0.574	-0.574	[3 - 30]
operatingCashFlowPerShareTTM	466.22	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	-82.25	2.00	-10.00	-10.00	[0 - 20]
debtEquityRatioTTM	0.692	-1.500	7.23	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.675	1.000	2.08	2.08	[0.2 - 0.8]
operatingProfitMarginTTM	0.0750	1.000	-0.500	-0.500	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.157	1.000	-0.240	-0.240	[0.2 - 2]
assetTurnoverTTM	0.293	0.800	-1.379	-1.103	[0.5 - 2]
Total Score				4.76

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	18.11	1.000	8.27	0	[1 - 100]
returnOnEquityTTM	0.0263	2.50	-0.526	-1.228	[0.1 - 1.5]
freeCashFlowPerShareTTM	-82.25	2.00	-10.00	-10.00	[0 - 30]
dividendYielPercentageTTM	0.0273	1.500	9.32	0	[0 - 0.4]
operatingCashFlowPerShareTTM	466.22	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	1.619	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.00300	1.500	-3.31	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.175	1.000	8.11	0	[0.1 - 0.5]
Total Score				3.01

Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.